Literature DB >> 18759928

Regulatory B cells as inhibitors of immune responses and inflammation.

Jean-David Bouaziz1, Koichi Yanaba, Thomas F Tedder.   

Abstract

B cells positively regulate immune responses through antibody production and optimal CD4(+) T-cell activation. However, a specific and functionally important subset of B cells can also negatively regulate immune responses in mouse autoimmunity and inflammation models. The lack or loss of regulatory B cells has been demonstrated by exacerbated symptoms in experimental autoimmune encephalitis, chronic colitis, contact hypersensitivity, collagen-induced arthritis, and non-obese diabetic mouse models. Accumulating evidence suggests that B cells exert their regulatory role through the production of interleukin-10 (IL-10) by either B-1, marginal zone (MZ), or transitional 2-MZ precursor B-cell subsets. We have recently found that IL-10-producing regulatory B cells predominantly localize within a rare CD1d(hi)CD5(+) B-cell subset that shares cell surface markers with both B-1 and MZ B cells. We have labeled this specific subset of regulatory B cells as B10 cells to highlight that these rare CD1d(hi)CD5(+) B cells only produce IL-10 and are responsible for most IL-10 production by B cells and to distinguish them from other regulatory B-cell subsets that may also exist. This review focuses on the recent progress in this field and the exciting opportunities for understanding how this unique B-cell subset influences diverse immune functions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18759928     DOI: 10.1111/j.1600-065X.2008.00661.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  192 in total

Review 1.  Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab.

Authors:  Laszlo Hegedüs; Terry J Smith; Raymond S Douglas; Claus H Nielsen
Journal:  Clin Endocrinol (Oxf)       Date:  2011-01       Impact factor: 3.478

2.  A novel mechanism of B cell-mediated immune suppression through CD73 expression and adenosine production.

Authors:  Hiroaki Kaku; Kai Fan Cheng; Yousef Al-Abed; Thomas L Rothstein
Journal:  J Immunol       Date:  2014-11-12       Impact factor: 5.422

3.  Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.

Authors:  Mayuka Horikawa; Veronique Minard-Colin; Takashi Matsushita; Thomas F Tedder
Journal:  J Clin Invest       Date:  2011-10-24       Impact factor: 14.808

Review 4.  Historical overview of immunological tolerance.

Authors:  Ronald H Schwartz
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-04-01       Impact factor: 10.005

Review 5.  Genetics, pathogenesis and clinical interventions in type 1 diabetes.

Authors:  Jeffrey A Bluestone; Kevan Herold; George Eisenbarth
Journal:  Nature       Date:  2010-04-29       Impact factor: 49.962

6.  [Regulatory B cells and their role in maintaining peripheral tolerance].

Authors:  T Tretter; H-M Lorenz
Journal:  Z Rheumatol       Date:  2010-11       Impact factor: 1.372

7.  Interleukin-10 mediated autoregulation of murine B-1 B-cells and its role in Borrelia hermsii infection.

Authors:  Vishal Sindhava; Michael E Woodman; Brian Stevenson; Subbarao Bondada
Journal:  PLoS One       Date:  2010-07-06       Impact factor: 3.240

Review 8.  L2pB1: a new player in autoimmunity.

Authors:  Xuemei Zhong; Thomas L Rothstein
Journal:  Mol Immunol       Date:  2010-12-31       Impact factor: 4.407

Review 9.  The double life of a B-1 cell: self-reactivity selects for protective effector functions.

Authors:  Nicole Baumgarth
Journal:  Nat Rev Immunol       Date:  2010-12-10       Impact factor: 53.106

10.  TSPAN33 is a novel marker of activated and malignant B cells.

Authors:  Van Phi Luu; Peter Hevezi; Felipe Vences-Catalan; José Luis Maravillas-Montero; Clayton Alexander White; Paolo Casali; Luis Llorente; Juan Jakez-Ocampo; Guadalupe Lima; Natalia Vilches-Cisneros; Juan Pablo Flores-Gutiérrez; Leopoldo Santos-Argumedo; Albert Zlotnik
Journal:  Clin Immunol       Date:  2013-08-15       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.